India, July 7 -- Revolution Medicines Inc. (RVMD), a late-stage clinical oncology company, on Tuesday announced the expedited phased review of Daraxonrasib in treating pancreatic ductal cancer by the Committee for Human use of Medicinal Products (CHMP) of the European Medicines Agency (EMA).
Daraxonrasib is an oral, multi-selective, RAS(ON) non-covalent tri-complex inhibitor. The drug previously received Breakthrough Therapy and Orphan Drug designations from the U.S. Food and Drug Adiministration (FDA) and was recognized as high priority under EMA's Cancer Medicines Pathfinder project.
The submission to the EMA was supported by significant results from the Phase 3 RASolute trial, which demonstrated unprecedented overall survival rates for...